Drug Discovery

Halozyme, Acumen partner for ENHANZE drug delivery technology

Halozyme Therapeutics and Acumen Pharmaceuticals have signed a global collaboration and non-exclusive license agreement for the ENHANZE drug delivery technology in Alzheimer's disease.

Noramco buys Drug Product Business Unit from Cambrex

US-based Noramco has acquired the Cambrex Drug Product Business Unit, which was formerly known as Halo Pharmaceuticals.

Altasciences concludes US laboratory facility expansion

Integrated drug development solution company Altasciences has completed the expansion of its new laboratory facility in Columbia, Missouri in the US.

Basilea, iNtRON sign deal for antibacterial agent

Basilea Pharmaceutica and iNtRON Biotechnology have signed an exclusive evaluation license and option agreement for the potential first-in-class clinical-stage antibacterial agent, tonabacase.

Canada’s PharmaDrug signs agreement to acquire Securedose Synthetics

Canadian company PharmaDrug has signed a definitive agreement to acquire Securedose Synthetics, a privately-held pharmaceutical research and development company.

ThermoGenesis opens cell and gene therapy facility in Sacramento, US

ThermoGenesis Holdings has opened a new 35,500ft² ReadyStart-IncuStart cGMP facility in Greater Sacramento in Northern California, US.

Caris, Moderna partner for mRNA-based oncology therapeutics advancement

Caris Life Sciences and Moderna have signed a new multi-year agreement for advancing mRNA-based oncology therapeutics.

Nona and BeiGene agree to expand antibody discovery partnership

HBM Holdings wholly-owned subsidiary Nona Biosciences has signed an agreement for the expansion of its antibody discovery collaboration with BeiGene.

Synaffix, ABL Bio partner to develop bispecific ADCs

Lonza company Synaffix has signed a licensing agreement with ABL Bio for the development of bispecific antibody drug conjugates (ADCs).